Back to all assets

Danaher Corporation DHR

equity

Price History

$0.0473$97.26$194.47$291.68
1978-12 · DCA start$0.0761

Time underwater

How far below its previous all-time high the price sat, each month. 0% means a new high.

-62.5%-41.7%-20.8%0.0%
1978-122026-08 · -29.4%

Worst drawdown: −63%, peaking Mar 1981 and bottoming Jun 1982 — 35 months below the prior high before recovering.

DCA Backtest

Invested
$57,300
Value today
$23,487,098
Return
+40889.7%
Months invested
573

Scenarios

Inflation — the same contributions merely keeping pace with CPI would be $118,149 today, so the real (inflation-adjusted) return is +19779.3%.

Lump sum instead — $57,300 all at once in Dec 1978: $154,873,610 (+270185.5%) — lump sum came out ahead.

Worst timing — same monthly amount started at the all-time high (Dec 2021): $5,250 on $5,700 invested (-7.9%).

⚠ Price returns only — dividends are not included. This understates the true return of dividend-paying shares, and any comparison against crypto (which pays no dividends) is biased against equities by roughly the dividend yield, compounded.

If this saved you a spreadsheet — buy me a coffee.

Every start month at once

Each cell is the return-to-date of £/$/€100-a-month DCA started that month. Click a cell to load it in the backtest above. The ringed cell is the all-time-high start — the worst timing scenario.

JFMAMJJASOND
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Legend:−50%−20%0%+50%+200%+1000%worst timing (ATH)Selected 1978-12: +40889.7%

About Danaher Corporation

Danaher Corporation is an American healthcare company headquartered in Washington, D.C.. It develops products used for advances in biotechnology, life sciences, and diagnostics. The company operates three divisions: biotechnology, which develops products for the development of therapeutics; life sciences, which develops products to identify causes of disease, new therapies, and to test and manufacture new drugs, vaccines and gene editing technologies; and diagnostics, which develops instruments, consumables, and software and services to diagnose diseases. (Wikipedia)

It's a listed company categorised under health care and life sciences tools & services, with a market cap of about $144.7B.

It rates Medium-Low Risk at 1.8/5, meaning the rated factors are mostly sound, with one or two areas worth watching.

What pushes the score up: sector / regulatory (3.0/5).

Scoring well: earnings quality at 1.0/5.

Not yet researched: concentration, governance. These are excluded from the score rather than guessed, so the real risk may be higher than what’s shown.

Ratings summarise sourced facts against fixed rules — not investment advice, and no substitute for your own diligence.

Risk Profile

Medium-Low Risk(1.8/5)80% rated

How these ratings work

Market / Volatility2.3/5 · weight 20%
  • Annualised volatility (3yr)2/521.2
  • Max drawdown from ATH3/562.5
  • Beta vs S&P 5002/50.86
Liquidity1.0/5 · weight 15%
  • Avg daily $ volume1/5991.1m
  • Float % of shares outstandingnot yet researched
Leverage / Financial2.0/5 · weight 20%
  • Debt / equity2/50.53
  • Interest coverage (EBIT / interest)not yet researched
Earnings Quality1.0/5 · weight 15%
  • 3yr EPS volatility1/58.9
Concentrationunrated · weight 10%
  • Largest customer, % of revenuenot yet researched
  • Geographic revenue concentrationnot yet researched
Governanceunrated · weight 10%
  • Board independence %not yet researched
  • Share structurenot yet researched
  • Litigation / audit historynot yet researched
Sector / Regulatory3.0/5 · weight 10%
  • Sector regulatory exposure3/5elevated

Linked Assets

Same sector, or return-correlated — worth knowing what else might move if this one does.